SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is trending following a massive surge in volume and price action driven by strong quarterly results, including record revenue growth and positive operating cash flow. The community is focused on the successful validation of the company's 'Butterfly Embedded' strategy, with intense debate centering on whether the stock can sustain its momentum or if it will face a typical post-hype correction.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors eagerly await a series of high-impact catalysts, including long-term trial results, while the community intensely debates potential M&A scenarios and the company's competitive positioning in the dermatology and immunology space.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is seeing strong community momentum following a joint research agreement with Honda to advance solid-state battery technology and manufacturing processes. Investors and traders are actively discussing the significance of this OEM validation, with many pointing to the partnership as a critical de-risking event that could accelerate commercialization and shift sentiment around the stock.

Accenture is a global professional services company that helps the world’s businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services, creating tangible value at speed and scale. The firm combines technology and leadership in cloud, data and AI with industry experience, functional expertise and global delivery capability. Its services include Strategy & Consulting, Technology, Operations, Industry X, and Song. It operates through the following geographical segments: North America, EMEA, and Growth Markets. The company was founded in 1989 and is headquartered in Dublin, Ireland.

Accenture plc - Ordinary Shares - Class A

Accenture is facing significant market pressure following a revenue outlook that missed expectations and a major acquisition strategy that sparked investor concerns over integration risks. While some community members remain focused on the company's long-term value and cybersecurity expansion, many are debating whether AI disruption and a shifting consulting model are permanently damaging the firm's growth prospects.

Roundhill ETF Trust - Roundhill Memory ETF

The Roundhill Memory ETF is seeing heightened interest as investors treat memory chips as a structural bottleneck for AI infrastructure rather than a traditional cyclical trade. Community sentiment remains aggressively bullish, with participants pointing to surging demand for HBM and upcoming earnings as catalysts for a potential multi-year re-rating of the sector.

Horizon Quantum Holdings Ltd. engages in the development of software tools. The company is headquartered in Singapore.

Horizon Quantum Holdings Ltd. - Ordinary Shares - Class A

Horizon Quantum Holdings is attracting significant community attention due to its low float and strategic partnerships with major industry players, fueling intense volume and speculation of a potential short squeeze. Traders are actively debating whether the companys quantum software focus represents a breakthrough infrastructure play or a speculative meme stock prone to volatility.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is facing significant regulatory headwinds as the FCC initiates an accelerated review of the company's broadcast licenses amid ongoing investigations into its corporate diversity policies. Meanwhile, community sentiment remains polarized, with investors weighing the potential impacts of executive leadership transitions and persistent political scrutiny on the stock's long-term performance.

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

XYO Network is currently generating significant social media activity as traders debate the project's long-term utility in the DePIN sector versus its history of volatile pump-and-dump price action. While some community members remain optimistic about future partnerships and institutional adoption, many participants are expressing frustration over stagnant price performance and the introduction of secondary tokens.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors react to the company's strong clinical pipeline and the validation of its CAN-2409 therapy, with significant community discussion focused on potential institutional accumulation and the stock's positioning ahead of major regulatory milestones. While some participants speculate about imminent trial catalysts and long-term buyout potential, others are actively debating the impact of institutional ownership versus the high levels of short interest in the biotech sector.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mount Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is trending as investors focus on its strong positioning within the underwater defense and autonomous systems market, particularly as geopolitical tensions increase global demand for naval mine countermeasures. Community discussion is dominated by anticipation for the upcoming Covelya Group acquisition, potential TSX and Nasdaq uplisting catalysts, and the belief that the company is effectively positioned to secure significant long-term growth through key defense partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.5%  - Should You Buy?

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 7.5% - Should You Buy...

Phathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Misses Estimates By $0.01 EPS

Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by...

Phathom Pharmaceuticals Q1 Earnings Call Highlights

Phathom Pharmaceuticals (NASDAQ:PHAT) reported first-quarter 2026 net revenue of $58.3 million, more than doubling the $28.5 million recorded in the same period a year ago, as the company emphasized...

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 16.2% After Earnings Miss

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 16.2% on Disappointing Earnings...

Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates

Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -5.88% and +2.76%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Phathom Pharmaceuticals (PHAT) Projected to Post Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) will be releasing its Q1 2026 earnings before the market opens on Thursday, April 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-30-phathom-pharmaceuticals-inc-stock...

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 6.8% - Time to Sell?

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.8% - Time to Sell...

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of "Moderate Buy" from Analysts

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine analysts that are presently covering the firm, MarketBeat.com...

Hennion & Walsh Asset Management Inc. Buys New Shares in Phathom Pharmaceuticals, Inc. $PHAT

Hennion & Walsh Asset Management Inc. bought a new position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 114,981 shares of the company's stock, valued at appro...

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Retail Interest in Phathom Soars As Firm Pledges Profit Path, Cuts Costs After Q1 Miss

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

PHATPhathom Pharmaceuticals Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PHAT News